A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies

NCT ID: NCT00953732

Last Updated: 2015-03-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

117 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A 12 month long-term follow-up study of patients who have achieved complete clearance of AK lesions at the Day 57 in the Phase 3 studies PEP005-016 or PEP005-025.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Actinic Keratosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Lesion count

Intervention Type DRUG

Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lesion count

Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AK lesion recurrence

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must have achieved complete clearance of AK lesions (lesion count = 0) at Day 57 in one of the following Peplin AK clinical studies: PEP005-016 or PEP005-025
* Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures

Exclusion Criteria

* Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)
* Early termination from study PEP005-016 or PEP005-025
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TKL Research, Inc.

INDUSTRY

Sponsor Role collaborator

Peplin

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eugene Bauer, MD

Role: STUDY_DIRECTOR

Chief Medical Officer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Burke Pharmaceutical Research

Hot Springs, Arizona, United States

Site Status

Center for Dermatology

Fremont, California, United States

Site Status

Dermatology Research Associates

Los Angeles, California, United States

Site Status

Dermatology Specialists Inc

Oceanside, California, United States

Site Status

Skin Surgery Medical Group Inc.

San Diego, California, United States

Site Status

Conant Medical Group

San Francisco, California, United States

Site Status

North Florida Dermatology Associates, PA

Jacksonville, Florida, United States

Site Status

University of Miami, Skin Research Camp

Miami, Florida, United States

Site Status

Atlanta Dermatology, Vein & Research Center, LLC

Alpharetta, Georgia, United States

Site Status

Medaphase Inc

Newnan, Georgia, United States

Site Status

Altman Dermatology Associates

Arlington Heights, Illinois, United States

Site Status

Glazer Dermatology

Buffalo Grove, Illinois, United States

Site Status

Laser Skin Surgery Center of Indiana

Carmel, Indiana, United States

Site Status

Deaconess Clinic, Inc

Evansville, Indiana, United States

Site Status

Dawes Fretein Clinical Research Group, LLC

Indianapolis, Indiana, United States

Site Status

The Indiana Clinical Trials Center, PC

Plainfield, Indiana, United States

Site Status

Pedia Research LLC

Owensboro, Kentucky, United States

Site Status

Hamzavi Dermatology

Fort Gratiot, Michigan, United States

Site Status

Minnesota Clinical Study Center

Fridley, Minnesota, United States

Site Status

Skin Specialists, PC

Omaha, Nebraska, United States

Site Status

Karl G. Heine Dermatology

Henderson, Nevada, United States

Site Status

Academic Dermatology Associates

Albuquerque, New Mexico, United States

Site Status

Mount Sinai School of Medicine

New York, New York, United States

Site Status

Dermatology Associates of Rochester, PC

Rochester, New York, United States

Site Status

Dermatology, Laser Vein Specialists of the Carolinas

Charlotte, North Carolina, United States

Site Status

Wake Research Associates

Raleigh, North Carolina, United States

Site Status

Oregon Medical Research

Portland, Oregon, United States

Site Status

Dermatology Research Associates

Nashville, Tennessee, United States

Site Status

DermResearch, Inc.

Austin, Texas, United States

Site Status

J & S Studies, Inc.

College Station, Texas, United States

Site Status

Suzanne Bruce and Associates, The Center for Skin Research

Houston, Texas, United States

Site Status

Progressive Clinical Research

San Antonio, Texas, United States

Site Status

Dermatology Associates of Tyler

Tyler, Texas, United States

Site Status

Center for Clinical Studies

Webster, Texas, United States

Site Status

Dermatology Research Center, Inc.

Salt Lake City, Utah, United States

Site Status

The Education and Research Foundation

Lynchburg, Virginia, United States

Site Status

Virginia Clinical Research, Inc

Norfolk, Virginia, United States

Site Status

Premier Clinical Research

Spokane, Washington, United States

Site Status

Southderm Pty Ltd

Kogarah, New South Wales, Australia

Site Status

St George Dematology and Skin Cancer Centre

Kogarah, New South Wales, Australia

Site Status

The Skin Centre

Benowa, Queensland, Australia

Site Status

South East Dermatology, Belmont Specialist Centre

Carina Heights, Queensland, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia

References

Explore related publications, articles, or registry entries linked to this study.

Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013 Jun;149(6):666-70. doi: 10.1001/jamadermatol.2013.2766.

Reference Type DERIVED
PMID: 23553119 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.fda.gov

Food and Drug Authority

http://www.tga.gov.au

Therapeutic Goods Administration

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PEP005-030

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.